Community reviews
Community reviews for i3hypermedia.com
Read visitor experiences about this website. Reviews do not change the independent technical Safety Score.
You need an account and verified email to post. Create a free account.
About i3hypermedia.com
On Aug. 26, the Food and Drug Administration accepted Neurocrine Biosciences' investigational new drug application for a Phase 2 study of NBI-1117567 in Alzheimer's cognition. The acceptance triggered a $10 million milestone payment to Nxera Pharma, the company that discovered the compound and licensed it to Neurocrine in 2021, according to Nxera's announcement. Ten million
See website report →
Community rating— / 5(0 approved reviews)
ModerationActiveSubmissions are checked before publication
Independent assessmentSeparateVisitor opinions never change the Safety Score
Manually moderated
Reviews (0)
Approved reviews only, newest first. Each submission is held for moderation.